Bibliographic information
Recommendation
Recommendations for the general population of women . In settings with high follow-up capacity (60% or greater) and sufficient ablative treatment capacity, WHO suggests using HPV DNA testing with extended or limited genotyping OVER treating all HPV-positive women or triaging all HPV-positive women with additional tests. In settings with high follow-up capacity (60% or greater) and sufficient ablative treatment capacity where HPV DNA extended genotyping is used, WHO suggests:
- treating all eligible women with ablative treatment who test positive for
carcinogenic HPV (cHPV) types 16 (group 1a), 18 and 45 (group 1b) and 31, 33, 35, 52 and 58 (group 1c); AND triaging women who test positive for cHPV types 39, 51, 56 and 59 (group 1d); OVER
- treating all eligible women with ablative treatment who test positive for cHPV types
16 (group 1a), 18 and 45 (group 1b), AND triaging women who test positive for cHPV types 31, 33, 35, 52, 58, 39, 51, 56 and 59 (groups 1c and 1d); OVER
- treating all eligible women with ablative treatment who test positive for cHPV types
16 (group 1a), 18 and 45 (group 1b) AND triaging women who test positive for cHPV types 31, 33, 35, 52 and 58 (group 1c) AND returning women who test positive for cHPV types 39, 51, 56 and 59 (group 1d) to routine screening.
Recommended in favor
Conditional
Certainty of evidence
Low
Notes and Remarks
To determine the type of treatment, women should be visually evaluated for eligibility for ablative treatment. Women not eligible for ablative treatment should be treated using large-loop excision of the transformation zone (LLETZ) or referred for further management if cancer is suspected.